Multidrug resistance (MDR) remains a major obstacle to effective pharmacotherapy in cancer, infectious diseases and central nervous system disorders. Resistance often arises through elevated activity ...

Cancer cells frequently develop the ability to expel anticancer drugs before they can work—a phenomenon called multidrug resistance (MDR)—which is one of the leading reasons why chemotherapy fails in ...

Multidrug resistance (MDR) remains one of the foremost obstacles to successful cancer therapy, arising when malignant cells evade the cytotoxic effects of structurally and functionally distinct agents ...

The discovery of a new preclinical compound with strong antifungal activity against multidrug-resistant pathogens is described in Nature. The drug, named mandimycin, is a member of a known family of ...

Multi drug resistant Klebsiella infections are rising in Indian ICUs, limiting antibiotic options and increasing risks for ...

Aligarh (UP), May 20 (PTI) Researchers at the Interdisciplinary Biotechnology Unit of Aligarh Muslim University have identified a new multidrug-resistant bacterial genome in wastewater flowing through ...

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) -- which is one of the leading reasons why chemotherapy ...

A new class of antibiotics has demonstrated fast-acting, potent activity against two of the WHO’s priority pathogens. Researchers from the University of Liverpool (UK) have developed NovItex, a new ...

A two-step nanoparticle system first blocks cancer cells' drug-expulsion mechanism, then releases chemotherapy combined with laser-driven heat to destroy resistant tumors.

Pediatric data on tigecycline remain limited, particularly for multidrug-resistant infections caused by gram-negative ...

A randomized clinical trial demonstrated the limits of rapid testing to determine the antibiotic susceptibility of ...

Rapid antimicrobial susceptibility testing of blood cultures is not superior to standard testing in patients with gram-negative bloodstream infections, according to the FAST trial.